Exhibiting at FOOD INGREDIENTS CHINA 2025

Synaura Biotechnology (Shanghai) Co., Ltd. is a cutting-edge biotechnology company headquartered in Shanghai, China. The company specializes in the research, development, manufacturing, and commercialization of Human Milk Oligosaccharides (HMOs), particularly 2’-Fucosyllactose (2’-FL). Leveraging advanced fermentation technology and proprietary processes, Synaura Biotechnology aims to enhance infant nutrition and promote health and wellness through innovative HMO products.

Core Business

The primary focus of Synaura Biotechnology (Shanghai) Co., Ltd. is the production of high-quality Human Milk Oligosaccharides (HMOs), which are essential for promoting beneficial gut bacteria, enhancing immune function, and supporting cognitive development in infants.

Product Categories

1. Human Milk Oligosaccharides (HMOs)

   • A class of carbohydrates naturally found in human breast milk that play a crucial role in promoting infant health and well-being.
   • Applications: Infant formula, dietary supplements, functional foods, and pharmaceutical formulations.

2. 2’-Fucosyllactose (2’-FL)

   • The most abundant and clinically studied HMO, known for its prebiotic, antimicrobial, and anti-inflammatory properties.
   • Applications: Infant nutrition, dietary supplements, gut health products, and immune support formulations.

Specialization and Core USP

Synaura Biotechnology’s Unique Selling Proposition (USP) lies in its ability to produce high-purity 2’-Fucosyllactose (2’-FL) through proprietary microbial fermentation processes. The company's technological expertise and state-of-the-art production facilities ensure consistent quality and scalability to meet the growing global demand for HMOs.

Key Strengths

• Advanced Fermentation Technology: Utilizing precision fermentation techniques to achieve high yields and purity of 2’-FL.
• Innovative R&D: A dedicated research team focused on developing novel HMOs and enhancing existing formulations for maximum efficacy.
• Quality Control Systems: Comprehensive quality assurance protocols to ensure product safety, purity, and compliance with international standards.
• Customizable Solutions: Providing tailored formulations to meet specific customer requirements in the infant nutrition and dietary supplement industries.

Financials

Although specific revenue figures are not publicly available, Synaura Biotechnology (Shanghai) Co., Ltd. continues to expand its market presence through strategic partnerships and collaborations with major players in the infant nutrition, pharmaceutical, and health supplement sectors. The company's revenue growth is primarily driven by the increasing global demand for HMOs and their proven health benefits.

Shipments Data

Synaura Biotechnology actively exports its HMO products, particularly 2’-Fucosyllactose (2’-FL), to various international markets, including:

• North America: High demand for 2’-FL in infant formula and dietary supplements.
• Europe: Growing market for functional foods and health products containing HMOs.
• Asia-Pacific: Increasing adoption of HMOs in infant nutrition and wellness products.
• Middle East & Africa: Emerging market for innovative nutritional solutions.

The company's strong distribution network and reliable logistics infrastructure ensure timely and efficient delivery of products to its global clientele.

Target Market

The primary markets served by Synaura Biotechnology (Shanghai) Co., Ltd. include:

• Infant Nutrition Industry: Providing high-quality HMOs for use in infant formula to enhance digestive health and immune function.
• Nutraceutical Industry: Supplying 2’-FL for dietary supplements targeting gut health, immunity, and cognitive development.
• Pharmaceutical Sector: Developing specialized HMO formulations for potential therapeutic applications.
• Functional Food Industry: Offering HMOs for incorporation into health-promoting foods and beverages.

Capabilities

• Production Capacity: State-of-the-art manufacturing facilities equipped with advanced fermentation and purification systems.
• Quality Assurance Systems: Stringent quality control protocols to ensure consistency, safety, and compliance with regulatory standards.
• Research & Development: Dedicated R&D teams working on novel HMO formulations and enhancing the functional properties of existing products.
• Customer Service: Providing customized solutions and technical support to meet the specific needs of clients across various industries.

Certifications and Compliance

Synaura Biotechnology (Shanghai) Co., Ltd. adheres to international quality standards to ensure product safety and efficacy. The company maintains certifications such as:

• ISO 9001: Quality Management System (QMS)
• ISO 22000: Food Safety Management System (FSMS)
• GMP Certification (Good Manufacturing Practice)
• GRAS Status (Generally Recognized As Safe) for 2’-Fucosyllactose (2’-FL)

These certifications demonstrate the company’s commitment to providing high-quality, safe, and effective HMO products that meet global regulatory requirements.

Customer Testimonials

While specific customer testimonials are not publicly available, Synaura Biotechnology (Shanghai) Co., Ltd. has earned a strong reputation for delivering reliable, high-purity HMOs that meet the stringent requirements of its clients. Its innovative approach to HMO production and dedication to quality have contributed to high levels of customer satisfaction.

Major Achievements

• Successful development of high-purity 2’-Fucosyllactose (2’-FL) through microbial fermentation technology.
• Continuous expansion of its product portfolio to include additional Human Milk Oligosaccharides (HMOs).
• Strategic partnerships with major players in the infant nutrition and dietary supplement industries.
• Recognition for technological innovation and contributions to the advancement of HMO production.

Promotional Activities

Synaura Biotechnology (Shanghai) Co., Ltd. promotes its products through direct client engagement, participation in industry conferences, trade shows, and scientific collaborations. The company's marketing strategy emphasizes innovation, quality, and customer-centric solutions.

Synaura Biotechnology (Shanghai) Co., Ltd. continues to expand its market presence by focusing on research, product innovation, and customer satisfaction. Its commitment to developing safe, effective, and high-quality HMOs ensures its continued growth and competitiveness in the global biotechnology industry.